NCT05292625CompletedPhase 1/2
Stem Cell Infusion in the Treatment of Patients with Neurological Sequelae After Ischemic Stroke
Outcomes of Umbilical Cord -derived Mesenchymal Stem Cell Infusion in Patients with Neurological Sequelae After Ischemic Stroke
Source: ClinicalTrials.gov · Last updated 6 Jan 2025
Brief summary (registry, in English)
This trial is to investigate the safety and potential therapeutic efficacy of allogeneic administration of umbilical cord-derived MSCs (UC-MSCs) in combination with standard neurological complications after ischemic stroke treatment in Vietnam.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 48 (actual)
- First submitted
- 14 Mar 2022
- Start date
- 7 Jul 2020
- Primary completion date
- 30 Dec 2022
- Lead sponsor
- Vinmec Research Institute of Stem Cell and Gene Technology
- Diseases
- Stroke
- NCT number
- NCT05292625
What you commit to
- Study type: Interventional · Phase 1/2
- Participants enrolled: 48
- From 7 Jul 2020 to the primary completion date, 30 Dec 2022
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Hematologic cause of stroke
- There is evidence of active infections, failure of heart, lung, liver, or kidney, respiratory distress syndrome, anemia, clotting disorder
- Cancer.
Other
- Pregnancy.
- Tracheostomy, coma, complete quadriplegia, vegetative.
Criteria the registry did not label
- Age: from 40 to 75 years.
- Gender: either sex
- Patients have been discharged/patients who are hospitalized but their general condition is stable:
- No need for vasopressor drugs
- No need for mechanical ventilation or oxygen support
- No signs of infection (fever, high WBC, high CRP/Procalcitonin)
- No kidney failure, liver failure, heart failure.
- Time from onset to study participation ≤ 24 months
- National Institutes of Health Stroke Scale (NIHSS) score \>=5
- Agree to participate in the study
Age in the registry: 40 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Vinmec Research Institute of Stem Cell and Gene Technology Coordinator of this site? Confirm its status | Hanoi | Vietnam | Unknown status |
Related publications
- Intrathecal versus intravenous umbilical cord mesenchymal stem cells for ischemic stroke sequelae.Stem Cells Transl Med · 2025 · PMID 41277536
This page is information, not medical advice. Discuss any trial with your doctor.